

Z-LEHD-FMK TFA Biochemical | Z-LEHD-FMKTFA biochemical

Z-LEHD-FMK TFA

CATALOG #
AAA228745


PRODUCT SYNONYMS

Z-LEHD-FMK TFA; Z-LEHD-FMKTFA biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	524746-03-0
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Z-LEHD-FMK (0.8 umol/kg; i.v. for 7 d) protects neurons, glia, myelin, axons, and intracellular organelles in spinal cord injury (SCI) rats[2]. Animal Model: Male Wistar albino rats (250-350 g) with SCI[2]. Dosage: 0.8 umol/kg. Administration: I.v. for 1 or 7 days. Result: Decreased the mean apoptotic cell count at 24 hours and 7 days postinjury.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Vanillinbananin, CAS 858956-96-4



Structure
Vanillinbananin, CAS 858956-96-4

ADDITIONAL INFORMATION

Related Product Information for Z-LEHD-FMKTFA biochemical	Z-LEHD-FMK TFA is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK TFA exhibits the neuroprotective effect in a rat model of spinal cord trauma.
References	1. Tanner JA, et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol. 2005 Mar;12(3):303-11.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.